RT Journal Article
SR Electronic
T1 Cumulative seroprevalence among healthcare workers after the first wave of the COVID-19 pandemic in El Salvador, Central America
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.06.22270565
DO 10.1101/2022.02.06.22270565
A1 Nakagama, Yu
A1 Rodriguez-Funes, Maria-Virginia
A1 Dominguez, Rhina
A1 Candray-Medina, Katherine-Sofia
A1 Uemura, Naoto
A1 Tshibangu-Kabamba, Evariste
A1 Nitahara, Yuko
A1 Kaku, Natsuko
A1 Kaneko, Akira
A1 Kido, Yasutoshi
YR 2022
UL http://medrxiv.org/content/early/2022/02/07/2022.02.06.22270565.abstract
AB Background The impact of novel coronavirus disease 2019 (COVID-19) on healthcare workers (HCWs) has been under-evaluated in Central America. We performed a seroepidemiological survey at a tertiary healthcare facility in El Salvador, where a large number of confirmed and far more suspected cases of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected HCWs had been documented during the first wave of the pandemic.Methods During January–February 2021, a total 973 HCWs were tested for SARS-CoV-2 antibodies. Participants completed a questionnaire asking of their demographic data. Occupational risk was assessed by statistically comparing the seropositivity rates among different occupational categories.Results Overall seroprevalence in HCWs reached 52.6% (512 of 973). Of the seropositive individuals, 61.7% (316 of 512) had experienced a documented COVID-19 diagnosis, while the remaining 38.3% (196 of 512) were unrecognized seroconversions. Differences in seropositivity rates existed between occupational categories; nurses demonstrated the highest at 63.8% (222 of 348, risk ratio 1.44, p < 0.0001), followed by auxiliary HCWs assigned to patient-related work (55.9%, 52 of 93), and medical doctors (46.7%, 50 of 107). Several non-patient-related professions showed above-average seroprevalence, suggesting substantial SARS-CoV-2 contacts outside the workplace: 60.0% (6 of 10) and 68.0% (17 of 25) for nutritionists and pharmacists, respectively.Conclusions SARS-CoV-2 seroprevalence exceeded 50% among HCWs in El Salvador, with disparity among occupational categories with different workplace exposure risks. Importance of not only nosocomial infection prevention but also screening for transmissions having occurred outside the workplace were highlighted to efficiently control nosocomial spreads during a pandemic wave.Key points Healthcare workers in El Salvador were tested for SARS-CoV-2 antibodies. Seroprevalence reached 52.6%, with disparity among occupation; nurses ranked highest at 63.8% seropositivity. Alongside nosocomial transmissions, high seroprevalence associated with non-patient-related work suggested substantial SARS-CoV-2 contacts outside the workplace.Competing Interest StatementYu Nakagama and Yasutoshi Kido report ownership of equity of Quantum Molecular Diagnostics, an Osaka City University spinout. Quantum Molecular Diagnostics targets infectious diseases to develop and provide innovative diagnostics. Yu Nakagama and Yasutoshi Kido also report receiving financial support outside of the work from Abbott Japan LLC, Japan.Funding StatementThis work was supported by Japan Agency for Medical Research and Development [grant numbers JP20jk0110021 and JP20he1122001]; the Osaka City University Strategic Research Grant 2021 for Young Researchers [grant number OCU-SRG2021_YR09]; and Japan Society for the Promotion of Science KAKENHI [grant number 21K09078].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Osaka City University Institutional Ethics Committee and the National Research Ethics Committee of El Salvador gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.